The aim of this study was to identify the genetic defect in two patients having cardiac dysfunction accompanied by neurological symptoms, and in one case MRI evidence of 
Introduction
Mitochondrial diseases (MDs) are a diverse group of disorders characterized by defects of the mitochondrial respiratory chain (DiMauro et al., 2008; Tucker et al., 2010) . These MDs can present at any age, and their clinical symptoms reflect a primary defect in tissues with high oxidative demand. The predominance of neuromuscular manifestations in MDs usually masks the presence of other clinical phenotypes, such as cardiac complications, but mitochondrial defects are being increasingly recognized to play a role in the pathogenesis of hereditary cardiomyopathies (Led et al., 2004) .
Sporadic or inherited mutations in mitochondrial DNA (mtDNA), specifically in the mtDNA transfer ribonucleic acid (tRNA) genes, or in the nuclear genome have been associated with hypertrophic and dilated cardiomyopathy (Papadopoulou et al., 1999; Hirano et al., 2001; Bénit et al., 2003; Taylor et al., 2003) . Cardiac conduction abnormalities have also been associated with different mtDNA rearrangements (Marín-García et al., 2002) . Hence, the cardiac and neuromuscular manifestations of these mutations share common pathophysiological processes, and mitochondrial cardiomyopathies (MCMs) can be either heart-specific or associated with a spectrum of other symptoms (Led et al., 2004) . However, heart-related manifestations in these patients are relatively mild compared to the severity of their neurological symptoms and the generalized muscle weakness that limits their activity.
One of the first mtDNA point mutations associated with a maternally transmitted MCM and myopathy was described in 1991 (Zeviani et al., 1991) , and the acronym MiMyCa was coined for this clinical syndrome. Since then, several mutations in the mitochondrial genome, mainly point mutations in mitochondrial tRNA (mt-tRNA) genes, have been associated with different MCM phenotypes (Hirano et al., 2001; Taylor et al., 2003.) . In an attempt to identify mtDNA mutations associated with MCMs, we performed a systematic search in a series of patients that were suspected of MCM. As a result of this study, two transitions in the MT-TV gene were identified, the putative m.1628C>T mutation and the previously described, but not functionally characterized, m.1644G>A sequence variation (Tanji et al., 2008) . In the present report, a selective reduction of the steady-state mt-tRNA Val level in the patient harbouring the m.1644G>A transition was found, confirming both the cardiac and the neurological involvement of this mutation.
Material and methods

Patient histories
Patient 1
This 14-year-old boy was the sixth child of healthy and non-consanguineous
Moroccan parents who had 7 children, all healthy except for one sister who died for of an unknown cause and another younger sister who presented short stature. Our patient presented short stature during the first years of life. At 9 years of age the parents observed palpebral ptosis, which required surgery. Physical examination revealed external ophthalmoplegia, pigmentary retinitis, and significant muscle atrophy in legs and arms. Cardiology study showed sinus rhythm and incomplete right bundle branch block in the electrocardiogram and mild hypertrophic cardiomyopathy in a transthoracic echocardiogram. Electromyogram showed a myopathic pattern. Serum laboratory parameters were normal. Likewise, urinary organic acids, plasma amino acids, and acylcarnitine profile were normal. Muscle biopsy was performed based on suspicion of a mitochondrial disorder.
Patient 2
This 32-year-old man reported that since the age of 21 he had progressive Quadriceps muscle biopsies were performed under local anesthesia. Serial frozen muscle sections were histochemically investigated for the presence of MD as described previously (Sciacco et al., 1996) . Gomori trichrome and succinate dehydrogenase stains were used to detect ragged red fibers, and they were scored as positive when seen in >1% of all fibers. The cytochrome oxidase stain was used to detect complex IV activity. Respiratory chain complexes I-IV activities were measured in total muscle homogenates as described previously (Martinez et al., 2001) , and related to those of citrate synthase (CS) to correct for mitochondrial volume.
Mitochondrial DNA sequencing
Total genomic DNA was extracted from skeletal muscle by standard protocols.
The complete mtDNA was amplified from total DNA in 24 overlapping 800-1000-bplong PCR fragments. Primers were carefully designed using the revised human mitochondrial DNA Cambridge reference sequence (Anderson et al., 1981; Andrews et al., 1999) . The PCR fragments were sequenced on both strands using an ABI 3710 (Applied Biosystems; Foster City, CA) sequencer and a dye terminator cycle sequencing kit (Applera, Rockville, MD).
PCR/restriction fragment length polymorphism (RFLP) analysis
The level of the m.1628C>T and m.1644G>A heteroplasmy in the MT-TV gene were determined by the last-hot-cycle technique as described previously (Moraes et al., 1993) . To screen for the novel m.1628C>T transition, a 434-bp fragment was amplified by PCR using primers corresponding to nucleotide ( 
Quantification of mitochondrial tRNA
Val mt-tRNA Val was quantified as described previously (Bornstein et al., 2005) .
Briefly, total RNA (5µg) extracted from skeletal muscle was incubated at 90°C for 5 min, electrophoresed through a 12% polyacrylamide-7M urea gel and electroblotted onto a Zeta-probe membrane. Hybridization was performed at 42ºC for 24 h. The 
Cardiac evaluation
Cardiac study included standard 12-lead ECG and transthoracic two-dimensional echocardiogram. Echocardiography was performed in the left lateral decubitus position using a Philips iE33 system (Philips Medical Systems, Eindhoven, The Netherlands).
Standard techniques were used to obtain M-mode, two-dimensional, and Doppler measurements (Limongelli et al., 2010) . The mean of three measurements was taken for each echocardiographic parameter. Patterns of hypertrophy were defined in accordance with previously published methods (Limongelli et al., 2010) .
Results
Histochemical and biochemical studies
Muscle biopsy was performed based on suspicion of a mitochondrial disorder in both patients, and appeared normal both morphologically and histochemically. The activity of the different complexes of the mitochondrial respiratory chain (MRC) was assessed in muscle homogenates obtained from the biopsies. Patient 1 showed a single enzyme defect of complex I and an important increase in the activity of citrate synthase in his skeletal muscle. Patient 2 showed a combined enzyme defect of complexes I and IV of the MRC, and also a high citrate synthase activity in his skeletal muscle (Table 1) .
Sequencing and PCR-RFLP analyses
In order to identify putative mutations in the mitochondrial genome, we purified and completely sequenced the mtDNA obtained from skeletal muscle of both patients.
Sequence analysis revealed a total of 49 nucleotide changes from the revised Anderson mtDNA sequence in patient 1 (Suppl Table 1A ) (Anderson et al., 1981; Andrews et al., 1999) . Haplogroup analysis showed the African origin of this subject, belonging to mitochondrial haplogroup L2a1. All sequence variations identified in this patient were previously described polymorphisms or synonymous substitutions within expressed sequences, except for the m.1628C>T transition identified in the MT-TV gene. This mtvariant was shown to be homoplasmic, involving all copies of the mtDNA in skeletal muscle from patient 1 ( Figure 1A ).
On the other hand, complete sequencing of the mtDNA from patient 2 revealed 35 sequence variations from the revised Anderson mtDNA sequence (Suppl Table 1B) , and indicated that this patient has a European origin (haplogroup X2b). Among the 35 mitochondrial variations, a previously described mutation, the m.1644G>A mutation in the MT-TV gene, was identified (Tanji et al., 2008) . This sequence change was found in heteroplasmy, and the patient harboured 94.4% mutant mtDNA in his skeletal muscle ( Figure 1B ).
Since this is a retrospective study, we could not verify the presence of the two transitions in other tissues from each of the two patients, and therefore we could not determine the heteroplasmy percentages of the mutated MT-TV gene in cardiac muscle, which may have given indications about the likely pathogenicity of these mt-variations.
Mitochondrial tRNA Val steady-state levels
In order to study the potential pathogenicity of both mutations we decided to investigate the steady-sate level of tRNA Val . Unfortunately, this study could only be carried out for the m.1644G>A mutation, because of we ran out of muscle tissue of patient 1. Total RNA was extracted from a muscle sample of patient 2 and from two control samples, and resolved by polyacrylamide gel electrophoresis. After electroblotting, the membrane was hybridized to specific mt-tRNA Val or control oligonucleotide probes as described in the Material and Methods section. Figure 2 shows the ratio of mt-tRNA Val to mt-tRNA Phe in patient 2 and control muscle samples.
Quantitative analysis of the autoradiograms showed a significant 67% decrease in the steady-state level of the tRNA Val harbouring the m.1644G>A mutation as compared to control samples (Figure 2 ).
Discussion
In this report, the clinical, histochemical, biochemical, and molecular diagnosis of two patients with suspected heart defect as a consequence of MD is described. This (Chalmers et al., 1997; McFarland et al., 2002; Blakely et al., 2004) . In accordance with these three reported cases, our two patients developed cardiac conduction abnormalities and hypertrophic cardiomyopathy within a neurological presentation, and because of this, together with radiographic findings, MD was suspected in both cases. Muscle biopsies did not confirm the clinical impression of MD as they were morphologically and histochemically normal in the two patients, in contrast with biopsy findings of patients with mutations in the MT-TV gene previously described (Chalmers et al., 1997; Tiranti et al., 1998; Sacconi et al., 2002; McFarland et al., 2002; Tanji et al., 2008; Horváth et al., 2009; Yan et al., 2010) . On the other hand, biochemical analysis showed a decrease in MRC complex I activity in muscle homogenate from patient 1, and a combined deficiency in the activity of MRC complexes I and IV from patient 2, as in most previous reports on mutations in the MT-TV gene (Chalmers et al., 1997; Tiranti et al., 1998; Sacconi et al., 2002; McFarland et al., 2002; Tanji et al., 2008; Horváth et al., 2009; Yan et al., 2010) . McFarland et al., 2002; DiMauro, 2006; DiMauro, 2011) . Although funcional analysis of this mutation was not possible due to the lack of sample, molecular data support that this nucleotide variation could be relevant from a functional point of view. Supporting data include: (i) the mutation is associated with a mitochondrial phenotype of hypertrophic cardiomyopathy with palpebral ptosis, external ophthalmoplegia, pigmentary retinitis, and muscle atrophy;
(ii) a single enzyme deficiency of MRC complex I and an increase in the activity of citrate synthase in skeletal muscle; (iii) the mutation involves a C to T change in the anticodon-stem of the MT-TV gene, which might interrupt the secondary structure of the anticodon-stem; (iv) mitochondrial nucleotide 1628 is quite conserved through evolution (Sprinzl et al., 1989; McFarland et al., 2004) , suggesting that the m.1628C>T
sequence variation may have a functional consequence; (v) this mutation was identified only once in a total of more than 4000 mtDNA sequences from public databases (Ingman and Gyllensten, 2003) and in more than 600 mtDNA sequences from our laboratory, which include controls and samples from a wide spectrum of pathological conditions associated to mitochondrial dysfunctions; and vi) as an indication for suspecting its pathogenic character, the other sample in which the m.1628C>T sequence variation was identified corresponds to a different haplogroup (haplogroup HV) (Torroni et al., 2003; Gallardo et al., 2006; DiMauro, 2011) . In consequence, we propose that, in the absence of functional studies, the m.1628C>T transition in the MT-TV gene is a good candidate to be responsible for the clinical phenotype observed in patient 1.
In patient 2, the heteroplasmic m.1644G>A transition was identified in skeletal muscle. Besides cardiac dysfunction, neurogastrointestinal manifestations were the main clinical phenotype in this patient. Gastrointestinal dismotility is not usually associated with mt-tRNA mutations, but it has been described in patients with MELAS caused by the mtDNA point mutation m.3243A>G (Shimotake et al., 1998; García-Velasco et al., 2003) . Recently, the m.1630A>G mutation in the MT-TV gene was reported in a child with MNGIE-like disease (Horváth et al., 2009 ). On the other hand, the m.1644G>A mutation was recently described in another patient, but with a different clinical phenotype (Tanji et al., 2008) . Our patient presented a more severe clinical phenotype, including cardiac involvement, which was absent in the aforementioned case report; this could be due to a higher heteroplasmy percentage in the muscle of our patient (94.4%) compared to that observed in the previously described patient (85%) (Tanji et al., 2008) . In addition, it is worth mentioning that the heteroplasmy percentage is higher in skeletal muscle of patients with MCMs and mutations in the MT-TV gene (Chalmers et al., 1997; McFarland et al., 2002; Blakely et al., 2004) than in patients without heart defects and mutations in the same gene (Taylor et al., 1996; De Coo et al., 1998; Tiranti et al., 1998; Sacconi et al., 2002; Tanji et al., 2008; Horváth et al., 2009 ).
Hence, mutant levels in skeletal muscle above 94% are probably required to affect the cardiac muscle in patients with MD associated with mutations in the MT-TV gene (Table 2 ).
To unravel the pathogenic mechanism of the m.1644G>A mutation, the mitochondrial tRNA Val steady state levels were studied. As shown in Figure 2 , there was a marked and selective reduction of the steady-state mt-tRNA Val level as compared to mt-tRNA Phe in skeletal muscle from patient 2 (27% of control values). Recent studies by us and others have shown that a decreased level of different mt-tRNAs inhibit mitochondrial protein synthesis (Enriquez et al., 1995; McFarland et al., 2002; Bornstein et al., 2005) . Accordingly, patient 2 presents a strong reduction in complex I
and IV activities in muscle homogenate. Moreover, our data are consistent with the m.1644G>A mt-tRNA Val being rapidly degraded. To date, the most pronounced decrease of the steady-state mt-tRNA Val in cardiac and in skeletal muscles has been observed in the presence of the mutation m. 1624C>T (McFarland et al., 2002 . This mutation, affecting the same mt-gene, is associated with infantile and fatal Leigh syndrome together with severe cardiac failure in one of ten children affected (McFarland et al., 2002) . Interestingly, tissues from all members of this pedigree were homoplasmic for the m.1624C>T mutation, as is the m.1628C>T transition in the skeletal muscle of patient 1 in our study. However, the marked variability in phenotype among different family members can not be explained by this mtDNA defect alone (Rorbach et al., 2008) . Our patient 2 had no known maternal family diagnosed of MD, and we could not confirm the presence of a low level mt-tRNA Val in cardiac muscle or in tissues from other maternal relatives. In addition, conformational changes or aminoacylation defects have also been found in other mt-tRNA point mutations as potential pathogenic mechanisms responsible for different clinical phenotypes (Enriquez et al., 1995; Bacman et al., 2003; Florentz et al., 2003; Bornstein et al., 2005) .
In our case, there was insufficient muscle sample and it could not be confirmed whether this mutation may also lead to a conformational change or impaired aminoacylation capacity of the mt-tRNA Val .
In conclusion, the two cases presented in this report reinforce the notion that cardiac manifestations are frequent in patients with mitochondrial disorders. Therefore, cardiac evaluation should be routinely performed at the time of diagnosis of MD in these patients. This study also shows that mitochondrial tRNA mutations associated with heart disease not only involve the leucine, lysine, or isoleucine tRNA genes, and that the mitochondrial valine tRNA gene should be sequenced when there is a high suspicion of mitochondrial cardiomyopathy. 
